Micronization is the reduction of active pharmaceutical ingredient particles to the low micron range, typically a D90 below 10 micron, in order to increase specific surface area. Because dissolution rate is proportional to surface area under the Noyes-Whitney relationship, micronization is the fastest and most widely used intervention for improving the dissolution-limited absorption of poorly soluble drugs, and it is a mandatory step for inhaled products where particle size governs lung deposition.
It is also the most over-prescribed fix in formulation development. Micronization solves dissolution rate. It does not solve equilibrium solubility, and applying it to the wrong problem wastes months.
The physics: why smaller particles dissolve faster
The Noyes-Whitney equation states that dissolution rate is proportional to the surface area available to the dissolution medium and to the concentration gradient between the particle surface and the bulk. Reducing particle diameter from 50 micron to 5 micron increases specific surface area roughly tenfold, and dissolution rate rises accordingly.
The critical qualifier is that this changes rate, not saturation solubility. Below roughly 1 micron the Ostwald-Freundlich relationship does begin to raise apparent solubility because of increased surface curvature, but at conventional micron scale the effect is negligible. This is the practical divide:
- BCS Class II (low solubility, high permeability): absorption is dissolution rate limited. Micronization frequently delivers a clear bioavailability improvement.
- BCS Class IV (low solubility, low permeability): absorption is limited by permeability as well. Micronization alone rarely fixes it.
- Very low solubility APIs (below roughly 10 micrograms per mL): even a fully micronised particle cannot dissolve enough in transit time. An amorphous solid dispersion, lipid system, or salt form is the correct route.
Milling technologies
Fluid energy jet mills (spiral or pancake mills). The dominant pharmaceutical micronization technology. Particles are accelerated by high-velocity gas jets, typically nitrogen at 5 to 10 bar, into a flat cylindrical chamber where they fracture by particle-on-particle collision. There are no moving parts and no grinding media, so contamination risk is very low and cleaning validation is straightforward. Classification is inherent: centrifugal force retains coarse particles in the grinding zone until they are small enough for the inward gas flow to carry them out. Typical output is a D50 of 1 to 5 micron.
Fluidised bed opposed jet mills. Opposing jets meet in a fluidised bed, with a dynamic air classifier above the chamber. Better energy efficiency and tighter distributions than spiral mills, with the classifier wheel speed providing an independent cut-point control. Preferred at commercial scale.
Pin mills and hammer mills. Impact mills reaching perhaps 20 to 50 micron. Useful for delumping and pre-milling ahead of a jet mill, not for true micronization.
Wet media milling (nanomilling). Zirconia or polymeric beads in a stirred chamber, with a stabiliser in the liquid phase. Reaches 100 to 500 nanometres, well beyond jet milling, but adds a drying step, media wear contamination risk, and stabiliser selection work.
Controlling particle size distribution
A single average number is not a specification. Meaningful control uses the distribution.
| Descriptor | What it means | Typical use |
| D10 | 10 % of volume below this size | Fines burden, cohesion and flow risk |
| D50 | Median diameter | Headline size, dissolution driver |
| D90 | 90 % of volume below this size | The critical release specification |
| Span, (D90-D10)/D50 | Distribution width | Batch-to-batch consistency |
Laser diffraction is the standard measurement technique. Two method decisions dominate reliability. First, dispersion mode: dry dispersion is fast but can under-report agglomeration or over-report it if pressure is too low, so a pressure titration should always be run to confirm the API is dispersed but not being further broken. Second, optical model: Fraunhofer approximation is inadequate below about 10 micron, and Mie theory with a measured refractive index should be used instead. For inhaled products, geometric size is not sufficient and cascade impaction (Next Generation Impactor) is required to determine aerodynamic diameter and fine particle fraction.
The inhalation case
For dry powder inhalers and pressurised metered dose inhalers, particle size is not an enhancement lever but the primary determinant of efficacy. Particles with an aerodynamic diameter above roughly 5 micron deposit in the oropharynx. Below roughly 1 micron they are largely exhaled. The therapeutic window is approximately 1 to 5 micron, and formulation work centres on holding the fine particle fraction stable across shelf life against the strong cohesive forces that particles in this range exert on each other.
Risks that micronization introduces
Surface amorphisation. High-energy milling disorders the crystal lattice, most severely at the particle surface. The resulting amorphous regions are thermodynamically unstable and recrystallise over time, causing particle bridging, agglomeration, and drifting dissolution results. This is the leading cause of a micronised API that performs well at release and poorly at stability.
Mitigation: conditioning. Controlled exposure to elevated humidity and temperature after milling deliberately relaxes the amorphous surface back to a stable crystalline state before the material enters formulation. This step is routinely omitted in early development and routinely regretted later.
Flow and handling deterioration. Below about 10 micron, van der Waals and electrostatic forces overwhelm gravity. Bulk density falls, cohesion rises, and blend uniformity, die filling, and capsule filling all become harder. A dissolution gain can be entirely erased by a content uniformity failure.
Polymorphic conversion. Mechanical energy input can trigger transformation to a different polymorph or a partially hydrated form. Powder X-ray diffraction before and after milling should be a standard control, not an investigation tool.
Containment. Micronised powders are highly airborne. For potent compounds (OEB 4 and 5), isolator-based or contained milling systems are mandatory, and this materially affects CDMO selection.
Choosing between particle engineering routes
| Approach | Typical size | Best suited to | Main drawback |
| Jet milling | 1 to 10 µm | BCS II, dissolution rate limited APIs, inhalation | Surface amorphisation, poor flow |
| Wet media milling | 0.1 to 0.5 µm | Very low solubility, injectable suspensions | Media contamination, stabiliser development, drying step |
| Spray dried dispersion | Molecular dispersion | Very low solubility where crystalline dissolution is inadequate | Physical stability, residual solvent, low bulk density |
| Hot melt extrusion | Molecular dispersion | Solvent-free amorphous systems | Thermal stress on API |
| Co-milling with excipient | 1 to 10 µm | Cohesive APIs needing flow support | Added blend complexity |
A useful sequencing rule: attempt micronization first, since it is the cheapest and best understood route with the lightest regulatory burden. Escalate to an amorphous system only when micronised crystalline material demonstrably cannot achieve the required exposure.
Frequently asked questions
What particle size counts as micronised? There is no regulatory definition. Industry convention is a D90 below 10 micron, with most micronised APIs sitting at a D50 of 2 to 5 micron.
Does micronization increase solubility? It increases dissolution rate, not equilibrium solubility. Meaningful solubility gains only appear in the sub-micron range through the Ostwald-Freundlich effect.
Is jet milling suitable for heat sensitive APIs? Yes. Gas expansion in the mill produces a cooling effect, and material residence time is short, so bulk temperature rise is minimal. Localised heating at collision points is still enough to cause surface amorphisation.
How much material is lost during micronization? Well-run jet milling typically recovers 90 to 97 percent, with losses concentrated in filter retention and line hold-up. Small development batches see disproportionately higher losses.
Disclaimer:
This article is for informational and educational purposes for life sciences professionals. It is not medical advice, formulation guidance, or a regulatory reference. Technical values are indicative and must be verified against current pharmacopoeial and regulatory requirements for your product and jurisdiction. Patients should consult a qualified healthcare professional regarding any medication.